ACC 2006

CHARISMA Trial: Add Clopidogrel to Aspirin? Not for Lower Risk Patients

Deepak Bhatt
Deepak Bhatt, Cleveland Clinic, Ohio
American College of Cardiology Annual Scientific Session March 11-14, 2006, Atlanta
The idea of adding clopidogrel anti-platelet therapy to standard aspirin therapy among patients with multiple risk factors for coronary disease is not supported by the CHARISMA study findings reported at the ACC conference in Atlanta. But Audio Medica heard from Deepak Bhatt of the Cleveland Clinic that the study found patients with established cardiovascular disease can benefit.

Similar Interviews

  • Warfarin Trumps Platelet Agents in Atrial Fibrilation
  • For atrial fibrillation, oral anti-coagulation remains the treatment of choice despite the potential of an anti-platelet regimen based on aspirin

  • Stroke Prevention: Aspirin is Different in Women
  • David Brown The effect of aspirin in preventing cerebrovascular disease is different in women as compared with men. A meta-analysis of

  • Aspirin Saves Women from Cardiovascular Death
  • Jeffrey Berger A study of 9 000 women with established cardiovascular disease has found that mortality is reduced by 25

    Post a comment

    Subscribe to Audio Medica Podcast